Moderate

Hereditary haemochromatosis (HFE iron overload)

iron-metabolism · Metabolic
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Inherited (usually HFE C282Y homozygous) excess intestinal iron absorption with parenchymal iron deposition in liver, pancreas, heart, joints, gonads, skin. Presents with fatigue, arthralgia, raised transaminases, diabetes, impotence, skin bronzing, cardiomyopathy or cirrhosis. Often detected on raised ferritin/transferrin saturation. Early treatment (venesection) prevents organ damage.

Red flags

  • Signs of decompensated cirrhosis or hepatocellular carcinoma
  • Cardiac arrhythmia or heart failure (iron cardiomyopathy)
  • New diabetes with bronzed skin ('bronze diabetes')
  • Ferritin >1000 µg/L (higher fibrosis/cirrhosis risk — needs liver assessment)

Assessment

Differential diagnosis

  • Secondary iron overload: transfusional, ineffective erythropoiesis (thalassaemia), chronic liver disease
  • Dysmetabolic hyperferritinaemia (fatigue + metabolic syndrome, NORMAL transferrin saturation)
  • Alcoholic / non-alcoholic fatty liver disease
  • Acute phase ferritin rise (inflammation, malignancy — check transferrin saturation + CRP)
  • Porphyria cutanea tarda (associated with iron overload)

Investigations

  • Fasting transferrin saturation (>45-50% is the key screening abnormality) + ferritin
  • HFE genotype (C282Y, H63D) if transferrin saturation and ferritin raised
  • LFTs, glucose/HbA1c (iron-induced diabetes), U&E
  • Fibrosis assessment: if ferritin >1000 µg/L or abnormal LFTs → liver MRI (iron quantification / T2*) +/- elastography or biopsy (cirrhosis risk)
  • ECG/echo and cardiac MRI if cardiac symptoms; testosterone/LH/FSH if hypogonadism
  • Screen first-degree relatives (genotype + iron studies)

Management

  • Confirm with transferrin saturation + ferritin, then HFE genotype
  • Stage organ involvement (liver fibrosis, diabetes, cardiac, gonadal, arthropathy)
  • Induction venesection: remove ~450-500 mL blood weekly, monitoring Hb/ferritin, until ferritin at low-normal target
  • Maintenance venesection every 2-4 months to keep ferritin ~50-100 µg/L
  • Lifestyle: limit alcohol, avoid vitamin C and iron supplements, caution with uncooked shellfish (Vibrio risk)
  • Use iron chelation only if venesection not tolerated (anaemia, poor venous access, severe cardiac disease)
  • Surveillance for hepatocellular carcinoma if cirrhotic (6-monthly ultrasound +/- AFP); treat diabetes/hypogonadism/arthropathy

Drugs & doses

Therapeutic phlebotomy (venesection) 450-500 mL weekly during induction; target ferritin 50-100 µg/L then maintenance
Deferasirox PO or desferrioxamine SC/IV chelation ONLY if venesection not feasible [verify local dosing]
Avoid oral iron and vitamin C supplements; limit alcohol
Treat secondary hypogonadism with testosterone replacement if indicated (see hypogonadism entry)

Disposition

Outpatient (hepatology/haematology). Venesection programme as day-case. Admit only for complications (cardiac, decompensated liver). Lifelong monitoring; HCC surveillance if cirrhotic.

Complications & pitfalls

  • Cirrhosis and hepatocellular carcinoma
  • Diabetes mellitus, hypogonadism, hypothyroidism
  • Dilated/restrictive cardiomyopathy, arrhythmia
  • Arthropathy (2nd/3rd MCP joints — 'iron fist'), chondrocalcinosis/pseudogout
  • Increased susceptibility to Yersinia, Vibrio, Listeria infections

Exam pearls

  • Raised fasting transferrin saturation (>45-50%) is the most useful early screen — ferritin alone is non-specific (acute phase).
  • Venesection is simple, cheap and effective; started before cirrhosis/diabetes it gives near-normal life expectancy.
  • Target maintenance ferritin ~50-100 µg/L; avoid over-depletion (anaemia).
  • Screen first-degree relatives — presymptomatic diagnosis prevents organ damage.
  • Avoid vitamin C and iron supplements; counsel on alcohol and shellfish (Vibrio vulnificus risk).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.